喹硫平联合丙戊酸镁缓释片治疗双相障碍抑郁患者效果分析
2020-09-15赵鑫郑占杰
赵鑫 郑占杰


【摘 要】 目的:双相障碍抑郁应用喹硫平联合丙戊酸镁缓释片治疗效果情况分析。方法:选取2018年12月-2019年12月本院诊治98例双相障碍抑郁患者资料,随机分为两组,对照组予以喹硫平,研究组予以喹硫平联合丙戊酸镁,分析两组PANSS(阳性与阴性症状量表)与HAMD评分(汉密顿抑郁表)、不良反应情况。结果:治疗后,研究组PANSS(37.78±3.52)与HAMD评分(5.76±2.14)分均比对照组(45.93±2.42)分、(8.35±2.29)分低,差异比较具统计意义(P<0.05);研究组发生嗜睡等不良反应12.24%与对照组10.20%,差异不具统计意义(P>0.05)。结论:双相障碍抑郁应用喹硫平联合丙戊酸镁缓释片治疗,能有效改善患者临床症状,且不会增加不良反应,具临床用药安全性。
【关键词】 双相障碍; 抑郁; 喹硫平; 丙戊酸镁; HAMD评分; 不良反应
【中图分类号】 R749.053 【文献标志码】A 【文章编号】1005-0019(2020)17-029-01
Abstract:Objective:To analyze the effect of quetiapine combined with magnesium valproate sustained-release tablets on the treatment of bipolar depression. Methods:Data from 98 patients with bipolar depression treated in our hospital from December 2018 to December 2019 were randomly divided into two groups. The control group was given quetiapine and the research group was given quetiapine combined with magnesium valproate. PANSS (positive and negative symptom scale), HAMD score (Hamilton depression scale), and adverse reactions in the two groups. Results:After treatment, both the PANSS (37.78 ± 3.52) and the HAMD score (5.76 ± 2.14) of the study group were lower than those of the control group (45.93 ± 2.42) and (8.35 ± 2.29). The difference was statistically significant (P < 0.05). ); 12.24% of narcolepsy and other adverse reactions in the study group and 10.20% in the control group were not statistically significant (P> 0.05). Conclusion:The treatment of bipolar depression with quetiapine combined with magnesium valproate sustained-release tablets can effectively improve the clinical symptoms of patients without increasing adverse reactions, and it is safe for clinical use.
Key words:bipolar disorder; depression; quetiapine; magnesium valproate; HAMD score; adverse reactions
雙相障碍属于临床常见精神科疾病,为心境障碍,主要表现为抑郁发作及躁狂发作,患者易激惹、情绪不稳定,影响患者正常生活质量[1]。双相障碍疾病具体发病原因并不十分明确,可能与心理、生物、社会环境等具相关性[2]。对双相障碍抑郁发作患者临床通常采用药物等干预,常用药包括喹硫平、丙戊酸镁等,但单独用药不理想[3]。为探究喹硫平联合丙戊酸镁缓释片治疗效果,本研究对选取2018年12月-2019年12月本院诊治98例双相障碍抑郁患者资料分析,报道如下:
1 资料与方法
1.1 一般资料 选取2018年12月-2019年12月本院诊治98例双相障碍抑郁患者资料,研究符合医学伦理,签署知情相关同意书,资料完整者;排除标准:该方案用药禁忌症,其他精神疾病者,妊娠、哺乳期者,肝肾功能障碍病;随机……
